KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

US8642010B2 · kind B2 · utility

Assignees

• Dyax Corp. · US
• Bracco Suisse SA · CH

Inventors

• Aaron Sato · Somerville, US
• Daniel J. Sexton · Melrose, US
• Daniel T. Dransfield · Hanson, US
• Robert Charles Ladner · Urbana, US
• Christophe Arbogast · Bonneville, FR
• Philippe Bussat · Cognac, FR
• Hong Fan · Princeton Junction, US
• Sudha Khurana · Santa Clara, US
• Karen E. Linder · Kingston, US
• Edmund R. Marinelli · Tucson, US
• Palaniappa Nanjappan · Princeton, US
• Adrian D. Nunn · Lambertville, US
• Radhakrishna K. Pillai · Kendall Park, US
• Sibylle Pochon · Worb, CH
• Feng Yan · Carouge, CH
• Kondareddiar Ramalingam
• Ajay Shrivastava · Princeton, US
• Bo Song · Princeton, US
• Rolf E. Swenson · Grayslake, US
• Mathew A. Von Wronski · Moorestown, US

Key dates

• Filing date: Jun 8, 2009
• Grant date: Feb 4, 2014
• Expiry date: Mar 18, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 μM), and dimer and multimeric constructs comprising these polypeptides.